Other novel PD-1/PD-L1 inhibitors are under investigation (Table 7), including atezolizumab, avelumab, and durvalumab, which are IgG monoclonal antibodies targeting PD-L1 (BP 545758), some of which have been approved for the treatment of NSCLC and urothelial cancer. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.